Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Zymeworks Inc ZYME

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

NDAQ:ZYME - Post Discussion

Zymeworks Inc > Slides to today’s conference…
View:
Post by Gringotts on Nov 09, 2021 6:46pm

Slides to today’s conference…

Link to the presentation slides used at today's conference  

https://ir.zymeworks.com/static-files/ec2ab511-256d-44c4-9b5e-aba93f3ec09c
 

Major take away:
BLOCKBUSTER peak sales potential for ZYME's line of cancer treatments.

Comment by ghayes on Nov 10, 2021 3:29am
So  their product is Zanidatamab for GastroIntestinal Cancer,  the clinical trials look good. Now they are setting up a full scale trial in 300 sites over 38 countries - looking for approval within 2, 3, 5 years if the study verifies the clinical trial results. - Could be a blockbuster., possibly one of the pharmacutical giants might buy it up as soon as they see the study is launched ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities